Methimazole Pill

PreclinicalSmall molecule

FFirst Affiliated Hospital of Harbin Medical University

Methimazole Pill is one of 14 small molecule programs targeting Thyroiditis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThyroiditisActive, not recruiting

Thyroid DiseaseActive, not recruiting

ThyroiditisPreclinical

Active, not recruiting

Thyroid DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Thyroid Disease

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Bayer Aspirin

Rayos

1 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 5

Olinvyk

Kenalog

Methimazole Pill

FFirst Affiliated Hospital of Harbin Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Methimazole Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methimazole Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methimazole Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Harbin Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFirst Affiliated Hospital of Harbin Medical University

Methimazole Pill

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Microbiota1 trial

Thyroid Disease1 trial

Thyroiditis1 trial

References

Drug Info

Quick Facts

Related News